Galapagos N.V.

Price Chart

Risk-Adjusted Performance

Also Listed On

Galapagos N.V. (GLPG) Price Performance

Galapagos N.V. (GLPG) trades on Euronext Amsterdam in EUR. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at EUR24.70, up 0.98% from the previous close.

Over the past year, GLPG has traded between a low of EUR22.04 and a high of EUR31.84. The stock has gained 12.1% over this period. It is currently 22.4% below its 52-week high.

Galapagos N.V. has a market capitalization of $1.63B, with a price-to-earnings ratio of 5.09.

About Galapagos N.V.

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that is in phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.